Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

Core Insights - Medtronic's stock has shown significant improvement, with its Relative Strength (RS) Rating rising from 67 to 82, indicating strong performance in the market [1] - The company reported solid Q2'2026 results, driven by robust revenue growth in its cardiovascular portfolio [1] - Medtronic's stock experienced a breakout due to a "clean beat" performance, particularly attributed to its pulsed field ablation technology [2] Company Performance - Medtronic's stock performance is highlighted by an increase in RS Rating, which is a key indicator for investors [1] - The company has achieved a notable revenue increase in its cardiovascular segment, contributing to its positive quarterly results [1] - The stock's breakout was characterized by a significant performance improvement, showcasing the effectiveness of its innovative technologies [2]

Core Insights - Upwork's stock has shown significant improvement in its Relative Strength (RS) Rating, achieving a score of 80, which indicates strong technical performance [1][4] - The stock has recently been upgraded to an RS Rating of 85, reflecting its rising price performance and market leadership [2][4] Company Performance - Upwork has met the benchmark of an 80-plus RS Rating, placing it among stocks with strong relative strength [4] - The company has demonstrated improved price strength, as indicated by its RS Rating climbing to 79 before the recent upgrade [4]

BREAKING: Futures Await Nvidia Earnings When putting together your watch list, look for stocks with an 80 or higher RS Rating, Edgewise Therapeutics (EWTX) stock now meets that criteria, with an increase from 80 to 88 Monday.  Risk Management In The Stock Market: How Much Money To Invest Now IBD's proprietary rating measures price performance with a 1 (worst) to 99 (best) score. Theâ€| Related news Vera Therapeutics Stock Earns RS Rating Upgrade 11/17/2025Vera Therapeutics sees its Relative Strength Rating ...

Group 1 - Ocular Therapeutix (OCUL) stock has achieved a Relative Strength (RS) Rating of 81, indicating strong market leadership [1] - Syndax Pharmaceuticals has received an RS Rating upgrade, reflecting improved technical performance [3] - Krystal Biotech's RS Rating has risen to 86, showcasing its strengthening position in the market [3] Group 2 - Genmab has entered into an $8 billion deal to acquire Merus, a company focused on cancer treatments, indicating strategic growth in the oncology sector [3] - Halozyme Therapeutics has seen an improvement in its RS Rating, suggesting positive market sentiment [3] - Incyte's stock has declined after its 2025 outlook did not meet Wall Street's optimistic expectations, highlighting potential challenges [3]

Core Insights - TG Therapeutics reported adjusted earnings of $2.43 per share and $161.7 million in sales for Q3, significantly exceeding analyst expectations of $0.22 earnings per share and $152.1 million in sales [1][2] - The earnings beat was primarily attributed to a one-time tax benefit of $365 million, which, if excluded, would have resulted in earnings closer to $0.15 per share [2] - The company raised its full-year sales guidance to $600 million, with $585 million expected from U.S. sales of its multiple sclerosis drug Briumvi [3] Financial Performance - Q3 adjusted earnings: $2.43 per share [1] - Q3 sales: $161.7 million [1] - Analyst expectations: $0.22 earnings per share and $152.1 million in sales [2] - Previous year Q3 earnings: $0.02 per share and $83.9 million in sales [2] - Revised full-year sales guidance: $600 million [3] Market Reaction - TG Therapeutics stock increased by 4.4% to $36.30 in premarket trading [3] - Shares are trading slightly above their 50-day moving average [3] Ratings and Upgrades - TG Therapeutics received an upgrade in its IBD SmartSelect Composite Rating from 94 to 97 [4][7] - The company is now part of an elite list of stocks with a composite rating above 95 [7]

Core Insights - The article emphasizes the importance of reliable information sources for investors, highlighting that historical performance does not guarantee future success [1][2] Group 1 - The information provided is intended for educational purposes and should not be considered as an offer or recommendation to buy or sell securities [1] - The data is sourced from what is believed to be reliable sources, but there is no guarantee regarding its accuracy or timeliness [1] - The ownership and estimate data are provided by LSEG and FactSet, respectively, indicating a reliance on established financial data providers [2]

Group 1 - Acuity Brands' stock is showing strong performance, currently priced at $347.90 with an increase of $8.83 or 2.6% [1] - The stock has formed a three-weeks-tight pattern, indicating a potential entry point at $348.62, with support at the 21-day line [1] - Acuity Brands has a Composite Rating of 95 out of 99 and ranks 30 out of 197 in its industry group, highlighting its strong market position [1] Group 2 - The overall market is experiencing a rise, with small-cap stocks also showing significant gains following recent breakouts [2] - Acuity Brands is noted for its rising relative strength, having achieved an RS rating over 90, placing it in an elite category of stocks [4] - The company is approaching key technical benchmarks, which could indicate further upward momentum in its stock price [4]